Peptic Ulcers and their Complications by Kumar, Akhilesh et al.
Kumar et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):256-261 
ISSN: 2250-1177                                                                                  [256]                                                                                 CODEN (USA): JDDTAO 
 
Available online on 15.06.2020 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits 
unrestricted non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                Review Article  
Peptic Ulcers and their Complications 
Akhilesh Kumar*, Dhanesh Kumar, Rajendra Kumar, Jhakeshwar Prasad, Mahendra Kumar, Prachita Joshi, 
Pratiksha Fulzele 
Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Raipur, (CG), Pin 493111, India. Affiliated to Chhattisgarh Swami 
Vivekananda Technology University (CSVTU). 
 
ABSTRACT  
Peptic ulcer disease (PUD) is an uncommon disorder of early life. Peptic ulceration of the stomach or duodenum is usually associated with 
abnormalities of the gastric mucosa such as gastritis and/or gastropathy. Gastritis and ulcers of the stomach and duodenum ca n be classified 
into either primary or secondary depending on their aetiologies. The majority of primary or unexplained peptic ulcers are the result of chronic 
inflammation caused by Helicobacter pylori infection. However, an increasing number of children with PUD without evidence of H. Pylori 
infection are now being seen. Rarely PUD is caused by hypersecretory states. Secondary ulceration occurs in response to acute stress from 
severe systemic illnesses such as sepsis, head injury, burns, and as sequelae to use of certain drugs. The prognosis for recovery from peptic 
ulcers is good as most patients will respond to treatment. 
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INTRODUCTION: 
Peptic ulcer disease (PUD) is a break within the internal 
lining of the stomach, first part of the small intestine or once 
in a while the lower esophagus.1, 7 An ulcer in the stomach is 
called a gastric ulcer, at the same time as that in the first a 
part of the intestines is a duodenal ulcer. The most common 
symptoms of a duodenal ulcer are waking at night time with 
upper abdominal pain or upper abdominal pain that 
improves with eating.1 With a gastric ulcer the pain might 
also get worse with eating.8 The pain is regularly described 
as a burningor stupid ache. Other symptoms consist of 
belching, vomiting, weight loss, or poor appetite. About a 
third of older human beings have no signs and symptoms. 1 
Complications may consist of bleeding, perforation and 
blockage of the stomach. Bleeding happens in as many as 
15% of people. 2 Common causes of gastric ulcer include the 
microorganism Helicobacter pylori and non-steroidal anti-
inflammatory drugs (NSAIDs).1 Other much less not unusual 
causes include tobacco, smoking, pressure due to extreme 
illness, Behcet disorder, Zollinger-Ellison syndrome, Crohn 
disease and liver cirrhosis, amongst others. 1, 3 Older people 
are greater sensitive to the ulcer-causing effect of NSAIDs.1 
The diagnosis is usually suspected because of the offering 
signs with affirmation by way of both endoscopy or barium 
swallow.1 H. Pylori can be diagnosed by testing of the blood 
for antibodies, a urea breath take a look at, testing the stool 
for symptoms of the bacteria, or a biopsy of the stomach.1 
Other situations that produce similar signs and symptoms 
consist of stomach cancers, coronary heart disease, and 
inflammation of the stomach lining or gallbladder 
inflammation.1 Diet does no longer play an important 
function in either causing or preventing ulcers.9 Treatment 
includes stopping smoking, stopping NSAIDs, preventing 
alcohol and giving medicinal drugs to lower stomach acid.[1] 
The medicine used to decrease acid is generally either a 
proton pump inhibitor (PPI) or an H2 blocker with four 
weeks of treatment initially recommended.1 Ulcers due to H. 
Pylori are trated with a combination of medications 
consisting of amoxicillin, clarithromycin and a PPI.4 
Antibiotic resistance is increasing and as a result treatment 
might not usually be effective.4 Bleeding ulcers may be 
treated with by using endoscopy, with open surgical 
procedure normally simplest utilized in cases in which it 
isn't a successful.2 Peptic ulcers are found in round 4% of the 
populace.1 New ulcers were located in around 87.4 million 
people global all through 2015.5 About 10% of individuals 
expand a peptic ulcer at some point or another of their 
existence. 10 They resulted in 267,500 deaths in 2015 down 
from 327,000 deaths in 1990. 6,11 The first description of a 
punctured peptic ulcer was in 1670 in Princess Henrietta of 
England.2 H. Pylori became first recognized as produce 
peptic ulcers by  Robin Warren and Barry Marshall within 
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the past due 20th century,4 a discovery for which they 
received the Nobel Prize in 2005. 12 
SIGNS AND SYMPTOMS: 
Followings are the signs and symptoms of peptic ulcer: 
Abdominal pain, traditionally epigastric strongly associates 
to mealtimes. In the condition of duodenal ulcers the pain 
appears around three hours after taking a meal and awakes 
the patient from rest. Bloating and abdominal completion. 
Water brash (This is more associated with gastro esophageal 
reflux disease). Nausea and abundant vomiting. Loss of 
appetite and weight reduction in gastric ulcer. Weight gain 
in duodenal ulcer as the pain is relived after meal. 
Hematemesis (vomiting of blood); this can happen due to 
bleeding directly from a gastric. Ulcer, or from harm to the 
esophagus from serious/continuing vomiting. 13 
COMPLICATIONS: 
Gastrointestinalbleeding is the most widely recognized 
complication. Sudden excess amount of bleeding can be life-
threatening.14 It is related with 5% to 10% death rate.15  
Perforation (a hole in the wall of the gastrointestinal tract) 
following a gastric ulcer regularly prompts disastrous 
outcomes whenever left untreated. Erosion of the gastro-
intestinal wall by the ulcer prompts to spillage of the 
stomach or intestinal substance into the abdominal cavity. 
Perforation at the anterior surface of the stomach prompts 
to acute peritonitis, initially chemical and later bacterial 
peritonitis. The primary sign is often sudden extreme 
abdominal pain. The death rate in this case is 20%.15 
Penetration is a form of perforation in where in the hole 
prompts and the ulcer proceeds into adjacent organs like as 
the liver and pancreas. 16 Gastric outlet obstructions is a 
narrowing of the pyloric canal by scarring and swelling of 
the gastric antrum and duodenum becau se of peptic ulcers. 
The person often presents with serious vomiting. 15 Cancer is 
included in the differential diagnosis (explained 
by biopsy), Helicobacter pylori as the etiological factor 
chance it 3 to 6 times more likely to develop stomach cancer 
from the ulcer. 16  
CAUSES OF PEPTIC ULCERATION: 
Infection: Helicobacter pylori 
Drugs: Non-steroidal anti-inflammatory drugs (including 
aspirin), Steroids, Bisphosphonates,   Immunosuppressant’s, 
Cocaine. 
Stress: Psychological, Physical e burns (Curling’s ulcer), 
Head injury (Cushing’s ulcer. Tobacco smoking, Alcohol 
intake, Zollingere Ellison syndrome (Gastrinomas), Age-
related decline in prostaglandin levels. 
EPIDEMIOLOGY: 
Epidemiological shows that PUD stays a moderately 
common condition worldwide, with yearly rate running 
from 0.10% to 0.19% for physician-diagnosed PUD and from 
0.03% to 0.17% for PUD diagnosed during hospitalization17. 
The 1-year predominance of physician diagnosed PUD was 
0.12–1.5%, and the 1-year prevalence of PUD diagnosed 
during hospitalizations was 0.10–0.19%17. The data show 
that the incidence of PUD has decreased over recent decades 
in many nations, in all likelihood because of the abatement 
in H. pylori infection, especially in Western populations. 
However, it is possible that the circumstance might be 
distinctive in Asian nations; an ongoing study in Korea 
revealed that the prevalence of H. pylori infection in 
relationship with GU was expanding with time, whereas H. 
pylori infection in DU was decreasing. 18 The most 
dependable investigation of physician-diagnosed 
predominance was from Sweden, reporting cross-sectional 
data illustrative of the general population 19; the 
examination in this manner included both symptomatic and 
asymptomatic PUD. The overall predominance of PUD saw in 
this study was 4.1%; 19.5% of all PUD cases recognized were 
asymptomatic. Comparing this prevalence with the lower 
rates obtained from other investigation of physician 
diagnosed PUD in primary care propose that a proportion of 
people with PUD remain undiagnosed. In people with 
asymptomatic PUD, extreme complications, for example 
gastrointestinal haemorrhage, may be the first indication of 
the disease. Haemorrhage is related with mortality 
approaching 10% and high recurrence 20. Literature shows 
that the reported incidence and prevalence of PUD have 
decreased over time in recent decades. However, fleeting 
trends in the rate of hospitalizations for complications of 
PUD changed, remaining unchanged or expanding in ongoing 
decades in two studies in Finland and the Netherlands 21-22, 
but declining over time in one study in Scotland 23. The 
lifetime risk for peptic ulcer in infected individuals ranges 
from 3% in the United States to 25% in Japan 24. 
ETIOLOGY: 
Till the last decade it has been evaluated that 95% of 
duodenal ulcer and 70% of gastric ulcer is credited because 
of H. pylori 25. About 14%–25% of gastric and duodenal 
ulcers are seen as related with NSAID use 26. Interaction data 
and randomized trial with NSAIDs and H. pylori annihilation 
therapy uncovered that the ulcer-inducing effects of both 
hazard factors are cumulative 27,28. However, their potential 
interaction in the producing of ulcer disease remains 
unidentified. Eradication of H pylori didn’t reduces the rate 
of ulcer relapse in existing long term NSAID users 29. PUDs 
posse a multifactorial disease pathway significantly 
represented by acid disbalance and low mucosal defense 
prompting inflammation. This is represented by hyper 
section of hydrochloric acid and pepsin. This causes an 
imbalance between gastric luminal element and degradation 
in the protective capacity of the gastric mucosal barrier for 
example mucus, secretion of bicarbonate, mucosal blood 
flow, and epithelial cell defense. On attack of acid and pepsin 
through a weakened area of the mucosal barrier prompts the 
release of histamine. Histamine stimulates parietal cells to 
secrete more acid. With the continuation of this endless loop 
resulting in disintegration to form the ulcer. 
1. Role of H. Pylori infection: 
H.pylori prompted ulcer development is impacted by a 
variety of host and bacterial factors. Ulcers mostly occur at 
sites of most serious mucosal inflammation 30. Decreased 
acid output, usually is the gastric transitional zone between 
corpus and antrum, offer ascent to gastric ulcer disease. If 
acid production is normal to high, the most serious 
inflammation normally is found in the distal stomach and 
proximal duodenum, offering ascend to juxta-pyloric and 
duodenal ulcer disease. Anperson’s definitive clinical 
outcome is dependent on the cytokine response and on the 
gastric acid secretion 30-31. An increase in stimulated acid 
production predisposes to duodenal ulceration and 
decreased acid formation predisposes to corpus gastritis or 
pangastritis which in turn predisposes to gastric ulceration, 
atrophic gastritis, and gastric carcinoma 30-31. The 
intragastric distribution of gastritis is thought to be 
dependent on host genetic factors, bacterial harmfulness 
factors and environmental factors including age at beginning 
of infection 31. 
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Figure 1: Depicting colonization of H. pylori in different regions of the stomach leading to various gastroduodenal diseases. 
 
Duodenal ulcers are related with H. pylori–induced antrum-
predominant gastritis, diminished somatostatin levels and 
enlarged gastrin and acid secretion 32. Development of 
gastric metaplasia in the duodenum further permits 
bacterial colonization, in this manner prompting to 
duodenitis and epithelial damage. Gastric ulcers are 
associated with corpus gastritis, which is accepted to 
damage the epithelium 32. Eradication of the infection 
recuperates peptic ulcer disease, restablidhes ordinary acid 
secretion and prevents ulcer relapse 33. Host response plays 
a critical role in H. pylori induced ulceration. The humoral 
immune system has only marginal pertinece for defensive 
immunity in H. pylori infection. H. pylori induce a Th1- 
polarized response that unfortunately doesn’t result in 
clearance of the infection. H. pylori is thought to constrol the 
host immune response and inflammation 34. The key 
activator of the innate immune response is presumably 
intracellular peptidoglycan 34. H. pylori is able for the 
inhibiting phagocytosis by macrophages by an as-yet 
unknown mechanism. IL-10-producing T cells appearto be 
essential in the control of inflammation and they enable the 
bacteria to persevere in gastric mucosa 34. Several cytokine 
genes have stable polymorphisms which are known to 
influence the level of cytokine production in response to H. 
pylori infection 35. The best known of these is interleukin-1β, 
a potent proinflammatory cytokine and the most potent 
known inhibitor of acid secretion 34. These cytokine 
polymorphisms may contribute to the danger of gastric 
adenocarcinoma, but their contribution to the danger of 
peptic ulceration is conflicting 36-37. 
2. Role of NSAIDs: 
Severe ulcer complications and gastrointestinal damages 
have been associated with NSAIDs, since last two decades. 
The risk of these complications have been found to increase 
with geriatric population [38], previous history of peptic 
ulceration, and presumably the initial three months of 
NSAID treatment.. Endoscopic examination reported more 
gastric than duodenal ulcers related with NSAID use, 
however, patients shows the result with gastrointestinal 
bleeding on NSAIDs may have a comparative frequency of 
gastric and duodenal ulceration. NSAIDs will in general 
impact the Cyclo-Oxygenase (COX) pathways which lead to 
generate of prostanoids (prostaglandins, prostacycline, and 
thromboxane). This effect the mucosal protection by 
diminishing the effectiveness of the mucus-bicarbonate 
obstruction; gastric acid, and possibly also pepsin, plausibly 
causing damage. As most NSAIDs are also weak acids may 
also be a contributory factor responsible ulceration 39. 
 
Figure 2: Pathogenesis of NSAIDs induced GI injury. 
3. Stress: 
Stress due to serious health problems for example, those 
requiring treatment in an emergency care unit is well 
described as a reason for peptic ulcers, which are also called 
as stress ulcers. While chronic life stress was once accepted 
to be the main cause of ulcers, this is no longer the case. It is, 
however, even now occasionally accepted to play a role. This 
may be due to the well documented impact of stress on 
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gastric physiology, expanding the risk in those with other 
causes for example H. pylori or NSAID use.  
4. Diet: 
Dietary factors, like as, spice consumption, were 
hypothesized to cause ulcers until late in the 20th century, 
however have been demonstrated to be of relatively minor 
importance. Caffeine and coffee, also commonly thought to 
cause or exacerbate ulcers, seem to have little 
effect. Similarly, while studies have discovered that alcohol 
consumption expands risk when associated with H. 
pylori infection, it does not appear to independently increase 
risk. Even when coupled with H. pylori infection, the increase 
is modest in comparison with the essential primary risk 
factor. 
5. Other: 
Other reasons for peptic ulcer disease includes: 
gastric ischemia, drugs, metabolic disturbances, 
cytomegalovirus (CMV), upper abdominal radiotherapy, 
Crohn'sdisease, and vasculitis. Gastrinomas (Zollinger–
Ellisonsyndrome), rare gastrin-secreting tumors, also cause 
multiple and difficult-to-heal ulcers. is still unclear if 
smoking increases the danger of getting peptic ulcers.  
DIAGNOSIS OF PEPTIC ULCER DISEASE: 
Peptic ulceration is a diagnosis usually confirmed by flexible 
upper GI endoscopy. An ulcer is defined as a mucosal break 
with a diameter greater than 5 mm. Ulcers may be single or 
multiple and most commonly affect the lesser curve of the 
stomach and the first part of the duodenum. Gastric ulcers 
should be biopsied in every instance to exclude malignancy. 
All patients with a gastric ulcer should undergo a repeat 
endoscopy in 6 to 8 weeks following treatment to ensure 
ulcer healing, and further biopsies should be taken if there is 
any evidence of ongoing ulceration. This should be repeated 
until the ulcer has fully healed. During endoscopy for 
suspected peptic ulceration it is also possible to test for H. 
pylori by biopsying the gastric mucosa for histological 
identification, microbiological culture or rapid urease test.  
The rapid urease test (CLO test_) is widely available and the 
most commonly used method of detecting H. pylori during 
endoscopy. It has the advantage of being quick, cost 
effective, with a high sensitivity (97%) and specificity 
(100%) when multiple biopsies are taken. If H. pylori 
infection is present the organism will produce the enzyme 
urease, which catalyses the conversion of urea (within the 
gel in which it is placed), resulting in the production of 
alkaline ammonium ions that will increase the pH and result 
in change in the colour of the gel from yellow to red. 
Histological identification and microbiological culture are 
costly and labour intensive and are therefore used less 
commonly. Less invasive diagnostic tests for H. pylori are 
also available for those patients who do not proceed to 
endoscopy. These include a urea breath test (sensitivity 95% 
and specificity 100%) that relies on the ability of H. pylori to 
metabolize orally administered carbon radio-labelled urea to 
carbon dioxide, which is exhaled by the patient and 
subsequently detected on the breath. Recent studies 
evaluating the increasingly common H. pylori stool antigen 
test as an alternative non-invasive test have demonstrated 
sensitivity and specificity of approximately 95%.[40] 
Serology for H. Pylori antigen is generally not recommended 
as it has potential to give false positive results in those with 
past but no current infection. False positive results can also 
occur in both the biopsy based urease and urea breath tests 
among patients receiving current acid suppression 
medication. 
MANAGEMENT OF UNCOMPLICATED PEPTIC 
ULCER DISEASE: 
The development of acid reduction pharmacological 
therapies and eradication strategies for H. pylori has 
revolutionized modern peptic ulcer management. The vast 
majority of patients with uncomplicated peptic ulcer disease 
can be treated and cured with medical treatment. The 
mainstay of management involves acid suppression, 
eradication of H. pylori (if present), and modification of 
etiological factors. With the introduction of H2-receptor 
antagonists (H2-blockers) came the ability to heal ulcers and 
control symptoms without the need for sub-optimal surgical 
procedures. These drugs, which include ranitidine and 
cimetidine, block the histamine receptor on gastric parietal 
cells and reduce the secretion of gastric acid.  
Subsequently, proton pump inhibitors (PPI) have now 
largely superseded the use of H2-blockers. PPIs, for example, 
omeprazole and lansoprazole, act by blocking the final 
process in hydrogen ion secretion by the mucosal parietal 
cells through H-K-ATPase inhibition. Studies have shown 
improved ulcer healing rates with the use of PPIs compared 
with H2 blockers, most likely due to the ability of these 
agents to completely suppress acid production and allow for 
no external stimulation from gastrin or vagal activity. PPIs 
are generally well tolerated but there are some concerns 
regarding long-term use with regards to the theoretical risk 
of developing vitamin B12 and iron deficiency, the proven 
potential for increased enteric infections such as Clostridium 
difficile, and potential increased risk of gastric cancer 
development through PPI-induced mucosal atrophy. More 
recently, some studies have suggested an association 
between long-term PPI use and increased risk of hip 
fractures, although this association has been refuted in other 
studies. Consideration should be given to supplemental 
intake of calcium and vitamin D in patients at increased risk 
of osteoporosis on long-term PPI treatment. In addition, PPI 
agents may cause hypomagnesaemia with prolonged use. It 
is therefore recommended that, while these risks are small 
and the benefits of PPI outweigh the risks in the majority of 
patients, the lowest efficacious dose should be administered 
and stopped if no longer clinically indicated. Proton pump 
inhibitors are equally effective in the treatment of both H. 
pylori positive and negative peptic ulceration. 
In those with H. pylori positive peptic ulceration, 
identification and eradication leads to resolution of gastric 
and duodenal ulcers in the majority of cases. Furthermore, in 
patients with unexplained persistent peptic ulceration 
initially found to be H. pylori negative, repeat tests should be 
used to confirm H. Pylori negativity. Eradication regimes 
vary by region due to local drug resistance patterns, but 
should be effective in approximately 80% of cases (Table 1). 
Effectiveness of eradication should be assessed by 
monitoring of symptoms. If symptoms persist then 
eradication should be confirmed with further diagnostic 
testing. Truly idiopathic ulcers are rare and, therefore, every 
effort should be made to identify potential etiological 
factors. In addition to the medical management described 
above, consideration should be given to addressing lifestyle 
measures that may contribute to the development of peptic 
ulceration, such as smoking cessation, reducing alcohol 
intake, and stopping NSAIDs (Table 2). 
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Table: 1 Examples of Helicobacter pylori eradication regimes 
Acid suppression Antibacterial medication 
 Amoxicillin Clarithromycin Metronidazole 
Twice daily dose of any PPI including 1 g twice daily 500 mg twice daily - 
Esomeprazole, Lansoprazole, Omeprazole, - 250 mg twice daily 400 mg twice daily 
Pantoprazole and Rabeprazole 1 g twice daily* - 400 mg twice daily* 
Seven day course for approximately 85% eradication. If penicillin allergic or recent use of metronidazole or a 
macrolide then an alternative regime should be used. *Formuse with omeprazole, amoxicillin dose 500 mg three 
times daily and metronidazole 400 mg three times daily. (from British National Formulary 67) 
 
Table 2: Factors associated with the development and progression of peptic ulcer disease 
Infective Helicobacter pylori infection, Cytomegalovirus, Herpes simplex virus 
Drugs Non-steroidal anti-inflammatory drugs, Acetylsalicylic acid (Aspirin), Corticosteroids 
Increased acid production Zollinger-Ellison syndrome (gastrinoma) 
Post surgical Anastomotic marginal following gastric surgery 
Malignancy  Adenocarcinoma, Lymphoma 
Autoimmune  Crohn’s disease 
Stress Secondary to burns (Curling’s ulcer), head injury (Cushing’s ulcer), trauma, sepsis and 
multiple organ failure 
Life style Alcohol intake, Smoking 
 
 
MANAGEMENT OF ACUTE BLEEDING PEPTIC ULCER 
DISEASE: 
Major complications of peptic ulcer disease include bleeding, 
perforation and gastric outflow obstruction. Of these, 
bleeding is the most common complication and is 
responsible for 50,00-70,000 emergency hospital admissions 
per year in the UK.[41] Approximately 5 to 10% of patients 
admitted with a bleeding peptic ulcer will die as a 
consequence of the bleed. Riskfactors for mortality include 
old age, associated comorbidity, NSAID use and 
hemodynamic instability on presentation. [41] 
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